TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02468375
Drug: mirabegron 50mg
Normalized name: MIRABEGRON 50MG SA TAB
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 434 OAB patient intake mirabegron 50mg/day for 12 weeks.
Study: NCT00487630
Drug: recombinant alpha-galactosidase A
Normalized name: Recombinant alpha-galactosidase A
DrugBank: Agalsidase alfa (DB15874)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT00414609
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren was available in 75 mg tablet, 150 mg tablet
Study: NCT01132690
Drug: Taliglucerase alfa
Normalized name: Taliglucerase alfa
DrugBank: Taliglucerase alfa (DB08876)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taliglucerase alfa for infusion every two weeks for 12 months
Study: NCT02203786
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose/maximum dose = 3-mg; route = oral. Participants assigned to the haloperidol antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol.
Study: NCT02203786
Drug: Fluphenazine
Normalized name: Fluphenazine
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose/maximum dose = 3-mg; route = oral. Participants assigned to the fluphenazine antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine.
Study: NCT02203786
Drug: Dexedrine
Normalized name: Dexedrine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose/maximum dose = 20-mg; route = oral. All participants will receive 2 doses (@ 20 mg) during Phase II - sessions 3, 4, with minimum 1 week between individual doses.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg D-amphetamine.
Study: NCT02256800
Drug: bevacizumab (Avastin)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab as target therapy
Study: NCT02256800
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: irinotecan as escalating dose according to UGT1A1 genotyping
Study: NCT02256800
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: combined with irinotecan
Study: NCT03592992
Drug: Spinal Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mcg of hydromorphone will be prepared in a non-identifiable syringe by central hospital pharmacy. The resulting solution will then be added to the spinal anesthetic mixture(fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
Study: NCT03592992
Drug: Spinal Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mcg of morphine will be prepared in a non-identifiable syringe by central hospital pharmacy.The resulting solution will be added to the spinal anesthetic mixture (fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
Study: NCT00006135
Drug: acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02388568
Drug: Lorcaserin
Normalized name: Lorcaserin
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorcaserin plus Lifestyle Modification
Study: NCT02944461
Drug: Dapsone 7.5 % gel
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone gel 7.5% applied once daily to truncal acne
Study: NCT03156621
Drug: Alirocumab
Normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Alirocumab SC Q2W
Study: NCT05571163
Drug: AMG 510
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT00799864
Drug: Rilpivirine
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive rilpivirine (RPV) tablet 25 milligram dose or an adjusted dose orally once daily in Cohort 1 (adolescents aged \>=12 to \<18 years) up to 240 weeks. Patients will receive RPV weight-adjusted dose orally once daily in Cohort 2 (children aged \>=6 to \<12 years) or 25 mg once daily for up to 48 weeks.
Study: NCT00799864
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type=exact, form= appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
Study: NCT00799864
Drug: Abacavir
Normalized name: Abacavir
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
Study: NCT00799864
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for 240 weeks (Cohort 1).
Study: NCT00799864
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
Study: NCT00799864
Drug: Emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
Study: NCT02350998
Drug: OTO-201
Normalized name: DB-OTO
DrugBank: DB-OTO (DB18278)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04072432
Drug: RBT-3
Normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration
Study: NCT03445845
Drug: Secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab : 150 mg per week for 5 weeks, and then every month by subcutaneous injection
Study: NCT03445845
Drug: TNF blocker
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNF blocker (originator or biosimilar) :~* infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~* etanercept: 50mg per week in subcutaneous injection,~* adalimumab: 40mg every other week in subcutaneous injection,~* certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~* golimumab: 50mg every month in subcutaneous injection, in case of overweight (\>100kg) an inadequate response, 100mg every month is allow.
Study: NCT04598919
Drug: Saracatinab
Normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg once daily by mouth for 24 weeks
Study: NCT00358280
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00358280
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00965991
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: patients received glyburide initial dose of 500 mg PO BID. Increased as necessary to a maximum dose of 2000 mg QD to control blood glucose
Study: NCT00965991
Drug: Glyburide
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of 2.5mg PO BID increased as necessary to a maximum dose of 20 mg (10mg BID) QD to control blood glucose
Study: NCT00353574
Drug: Darusentan
Normalized name: Darusentan
DrugBank: Darusentan (DB04883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darusentan capsules administered orally once daily
Study: NCT00183391
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
Study: NCT00183391
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
Study: NCT01392495
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200 mg or 400 mg qd
Study: NCT01098357
Drug: Biochaperone PDGF-BB Low dose
Normalized name: PDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BioChaperone PDGF-BB low dose is applied as a spray every two days at the dose of 12.5 µg/cm2 for up to 20 weeks
Study: NCT01098357
Drug: Biochaperone PDGF-BB High dose
Normalized name: PDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BioChaperone PDGF-BB high dose is applied as a spray every two days at the dose of 25 µg/cm2 for up to 20 weeks
Study: NCT01098357
Drug: Regranex
Normalized name: Regranex
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regranex gel is applied once daily at the dose of 6.25 µg/cm2 for up to 20 weeks
Study: NCT01098357
Drug: Biochaperone PDGF-BB Very Low Dose
Normalized name: PDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
Study: NCT00647023
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg metformin x 2 daily during 8 months
Study: NCT00094666
Drug: MK0928, gaboxadol / Duration of Treatment - 6 weeks
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04744532
Drug: Bosutinib (Phase 1 part)
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive 100 mg, 200mg, 300mg or 400 mg of bosutinib once daily, orally.
Study: NCT04744532
Drug: Bosutinib (Phase 2 part)
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive 200mg/day or 300mg/day of bosutinib once daily, orally.
Study: NCT04505280
Drug: Lidocaine 1% Injectable Solution
Normalized name: lidocaine 1% injectable solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Greater occipital nerve and cervical region injections once a week for 4 weeks
Study: NCT00395512
Drug: Alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin tablets.
Study: NCT00395512
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone tablets.
Study: NCT02373163
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm: Active Comparator: Diuretic Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Calcium-channel blocker Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Angiotensin Receptor Blocker Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
Study: NCT02373163
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
Study: NCT02373163
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
Study: NCT00483509
Drug: NGR-hTNF
Normalized name: NGR-hTNF
DrugBank: Tengonermin (DB16689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv q3W 0.8 mcg/sqm NGR-hTNF
Study: NCT04017468
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized into the treatment arm will receive 1-2 g of vancomycin powder (Vancocin® i.v.) which will be administered above the closed muscle fascia (suprafascially) before closing the subcutaneous tissue and skin. The dose of the drug will depend on the length of the skin incision: 1 g for incisions ≤ 20 cm, 2 g for incisions ≥ 20 cm.
Study: NCT01570192
Drug: IV meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
Study: NCT01570192
Drug: I.V. Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage
Study: NCT01570192
Drug: Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.
Study: NCT01986751
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01986751
Drug: ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00997191
Drug: Intravitreal triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal preservative-free triamcinolone (4mg) associated to focal photocoagulation for diabetic macular edema on baseline; Re-treatment at weeks 20 and 40 if CMT\>275um
Study: NCT00997191
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (1.5mg) associated to focal photocoagulation for diabetic macular edema at baseline; Re-treatment at weeks 20 and 40 if CMT\>275um
Study: NCT01091532
Drug: UK-396,082
Normalized name: UK-396,082
DrugBank: UK-396,082 (DB12099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.
Study: NCT01091532
Drug: UK-396,082
Normalized name: UK-396,082
DrugBank: UK-396,082 (DB12099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.
Study: NCT01091532
Drug: UK-396,082
Normalized name: UK-396,082
DrugBank: UK-396,082 (DB12099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.
Study: NCT01091532
Drug: UK-396,082
Normalized name: UK-396,082
DrugBank: UK-396,082 (DB12099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK-396,082 given orally, once on Days 1 \& 14, and twice daily on Days 3-13.~The decision to proceed to the next higher dose will be made jointly by the Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts. Dependent on the emerging safety, tolerability and PK data, Cohort 4 may be recruited to study a higher (or lower) dose of UK-396,082 in order to characterize further the safety, toleration and PK and/or to define the maximum tolerated dose. The dose in Cohort 4 will be selected such that the predicted Cmax will not exceed 46 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.
Study: NCT03387774
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in both arms received concurrent cisplatin chemotherapy:~100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.
Study: NCT03387774
Drug: Ulinastatin
Normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the experimental group were received ulinastatin:~Ulinastatin (UTI): ulinastatin was intravenous drip at a dose of one hundred thousand units added to 100 ml of 0.9% normal saline every time, 3 times every radiation day, and until the end of radiotherapy.
Study: NCT00984633
Drug: Rocuronium bromide (Org 9426)
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.6 mg/kg injection intubation dose
Study: NCT00984633
Drug: Rocuronium bromide (Org 9426)
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9 mg/kg injection intubation dose
Study: NCT00984633
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5-2.0% intravenous maintenance anesthesia
Study: NCT00984633
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-10 mg/kg/hr maintenance anesthesia
Study: NCT00485849
Drug: Atomoxetine Hydrochloride
Normalized name: Atomoxetine Hydrochloride
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00576238
Drug: betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application according to a fixed schedule for three weeks
Study: NCT04916665
Drug: Teduglutide
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bridging intestinal failure with teduglutide until reconstruction
Study: NCT01686633
Drug: Fluticasone Furoate/ Vilanterol 200/25 mcg
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate/ vilanterol will be available as 200/25 mcg Novel dry powder inhaler (NDPI) with 30 doses per device and 200/25 mcg per actuation
Study: NCT03561584
Drug: Sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be initiated on a low dose of sulfasalazine (500 mg) twice daily (bid). Dosage will be increased throughout the study.
Study: NCT00003031
Drug: amphotericin B deoxycholate
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003031
Drug: voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004163
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03139253
Drug: amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxicillin 1000 mg bid. for 14 days
Study: NCT03139253
Drug: tinidazole
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tinidazole 500 mg bid. for 14 days.
Study: NCT03139253
Drug: levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: levofloxacin 500 mg qd. for 14 days.
Study: NCT03139253
Drug: furazolidone
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: furazolidone 100 mg bid. for 14 days.
Study: NCT01686633
Drug: Fluticasone Furoate/ Vilanterol 100/25 mcg
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate/ vilanterol will be available as 100/25 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
Study: NCT01686633
Drug: Fluticasone Furoate 100 mcg
Normalized name: fluticasone furoate 100 mcg/inh inhalation powder
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate will be available as 100 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
Study: NCT01641120
Drug: Avonex
Normalized name: Avonex
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular injection administered using 25 gauge or 30 gauge needle
Study: NCT03139253
Drug: Ilaprazole
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 5 mg bid. for 14 days.
Study: NCT02864914
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: drug
Study: NCT02864914
Drug: DPP-4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug